marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-07-2024
Revance Therapeutics Financial Ratios 2011-2024 | RVNC
Annual Financial Ratios Revance Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-1.5 | -7.1 | -3.2 | -5.2 | -6.1 | -4.5 | -8.5 | -6.0 | -6.9 | -5.0 | - | - | - |
P/S |
2.0 | 19.0 | 11.6 | 96.3 | 2349.8 | 171.1 | 3917.7 | 1799.3 | 1681.9 | 815.2 | - | - | - |
EPS |
-3.8 | -4.9 | -4.2 | -4.9 | -3.7 | -3.9 | -4.0 | -3.2 | -3.0 | -3.2 | 1.2 | -290.5 | - |
EV (Enterprise Value) |
972 M | 2.98 B | 1.25 B | 1.48 B | 914 M | 646 M | 770 M | 504 M | 326 M | 157 M | 176 M | 226 M | 195 M |
EBITDA per Share |
-3.61 | -4.24 | -3.77 | -4.53 | -3.72 | -3.9 | -3.85 | -2.76 | -2.89 | -2.58 | - | - | - |
EV/EBITDA |
-4.8 | -5.2 | -4.9 | -4.0 | -6.4 | -6.1 | -4.3 | -2.9 | - | - | - | ||
PEG |
3.93 | -2.52 | -0.39 | -0.49 | -0.89 | -2.56 | 0.33 | 1.14 | -1.01 | 0.52 | - | - | - |
P/B |
-3.2 | 199.9 | 13.1 | 3.9 | 4.3 | 4.4 | 3.8 | 3.0 | 2.0 | 1.8 | - | - | - |
P/CF |
-2.2 | -13.0 | -4.1 | -8.3 | -8.9 | -5.7 | -10.5 | -8.5 | -8.6 | -5.0 | - | - | - |
ROE % |
213.71 | -2828.75 | -410.85 | -75.37 | -70.70 | -97.90 | -44.85 | -50.41 | -29.01 | -35.67 | - | - | - |
ROA % |
-67.72 | -61.25 | -52.96 | -39.17 | -46.85 | -62.99 | -40.78 | -43.68 | -26.64 | -32.69 | - | - | - |
ROCE % |
208.95 | -2713.95 | -401.16 | -72.98 | -54.95 | -73.38 | -42.76 | -42.85 | -27.42 | -28.56 | - | - | - |
Current Ratio |
0.8 | 1.0 | 1.1 | 2.1 | 7.2 | 6.5 | 13.6 | 9.8 | 21.1 | 16.9 | - | - | - |
DSO |
30.4 | 20.2 | 12.1 | 21.8 | - | 2642.8 | 66.9 | 7331.6 | 192.2 | 285.9 | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
30.4 | 20.2 | 12.1 | 21.8 | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
30.4 | 20.2 | 12.1 | 21.8 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Revance Therapeutics
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.37 | -0.36 | -0.58 | - | -1.63 | -0.8 | -0.74 | - | -1.17 | -0.88 | -0.94 | - | -1.1 | -1.07 | -1.08 | - | -1.34 | -1.12 | -1.15 | -0.99 | -0.96 | -0.86 | -0.85 | -1.12 | -0.91 | -0.94 | -0.97 | -1.12 | -1.01 | -0.9 | -0.94 | -0.95 | -0.64 | -0.88 | -0.71 | -0.83 | -0.81 | -0.71 | -0.65 | -0.6 | -0.6 | -0.69 | -1.93 | -53.63 | -55.9 | -75.25 | 25.54 | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.3 | -0.33 | -0.49 | - | -0.43 | -0.66 | -0.52 | - | -1.02 | -0.77 | -0.83 | - | -0.86 | -0.9 | -0.99 | - | -1.18 | -1.01 | -1.12 | -0.88 | -0.93 | -0.87 | -0.87 | -1.04 | -0.89 | -0.94 | -0.98 | - | -0.98 | -0.88 | -0.93 | - | -0.59 | -0.83 | -0.69 | - | -0.72 | -0.66 | -0.62 | - | -0.57 | -0.64 | -0.99 | - | -34.4 | -52.3 | -45.2 | - | - | - | - | - | - | - | - |
ROE % |
239.06 | 348.62 | 68.41 | 105.79 | 47.66 | -143.39 | 2442.97 | 2025.00 | 1963.11 | 1959.33 | -414.48 | -129.99 | -151.70 | -111.52 | -88.94 | -54.44 | -74.55 | -71.20 | -71.59 | -70.70 | -78.49 | -82.68 | -89.50 | -97.90 | -85.12 | -73.97 | -60.56 | -46.61 | -46.63 | -45.39 | -49.28 | -50.41 | -44.00 | -41.42 | -34.16 | -29.01 | -28.35 | -28.70 | -29.61 | -35.67 | -21.22 | -7.65 | 7.40 | 52.83 | 46.43 | 40.80 | 33.29 | - | - | - | - | - | - | - | - |
ROA % |
-52.80 | -71.06 | -74.75 | -48.69 | -60.60 | -45.98 | -45.65 | -32.90 | -45.68 | -46.56 | -46.89 | -34.65 | -45.93 | -44.43 | -41.58 | -28.29 | -41.61 | -42.50 | -45.08 | -46.85 | -51.48 | -53.81 | -57.88 | -62.99 | -58.78 | -54.64 | -48.67 | -42.37 | -41.75 | -40.18 | -43.13 | -43.68 | -38.58 | -36.73 | -30.79 | -26.64 | -26.01 | -26.32 | -27.14 | -32.69 | -69.83 | -101.78 | -147.10 | -367.58 | -323.06 | -283.85 | -231.61 | - | - | - | - | - | - | - | - |
ROCE % |
129.22 | 144.80 | -92.17 | 0.13 | -53.05 | -141.59 | 2267.25 | 1901.69 | 1841.17 | 1833.83 | -402.42 | -126.95 | -147.56 | -107.65 | -85.13 | -52.15 | -72.63 | -70.88 | -72.98 | -72.93 | -78.84 | -83.07 | -89.70 | -97.95 | -83.00 | -71.32 | -57.32 | -31.48 | -41.49 | -40.08 | -43.69 | -34.76 | -42.17 | -39.57 | -32.52 | -19.95 | -27.79 | -28.22 | -28.98 | -21.66 | -16.41 | -3.33 | 11.19 | 18.59 | 18.59 | 13.35 | 6.14 | - | - | - | - | - | - | - | - |
Current Ratio |
0.7 | 0.8 | 0.8 | 0.8 | 0.8 | 1.1 | 0.9 | 1.0 | 1.3 | 1.0 | 1.0 | 1.1 | 1.3 | 1.4 | 1.6 | 2.1 | 2.1 | 2.1 | 2.1 | 3.0 | 3.0 | 3.0 | 3.0 | 2.8 | 2.8 | 2.8 | 2.8 | 11.0 | 11.0 | 11.0 | 11.0 | 7.5 | 7.5 | 7.5 | 7.5 | 12.2 | 12.2 | 12.2 | 12.2 | 11.9 | 11.9 | 11.9 | 11.9 | 0.4 | 0.4 | 0.4 | 0.4 | - | - | - | - | - | - | - | - |
DSO |
64.3 | 46.0 | 50.5 | - | 35.8 | 27.2 | 26.6 | - | 27.2 | 16.2 | 14.1 | - | 5.3 | 14.1 | 24.1 | - | 43.5 | 558.2 | 1438.8 | - | - | - | 4431.2 | 5059.0 | 1043.1 | 3591.5 | 6394.1 | 59.2 | - | - | 77.9 | 77.9 | - | - | 45.6 | 45.6 | - | - | 182.5 | 1046.9 | 978.8 | 1200.8 | 580.7 | 66.4 | 129.9 | 273.8 | 136.9 | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 25532.6 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 54997.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
64.3 | 46.0 | 50.5 | - | 35.8 | 27.2 | 26.6 | - | 27.2 | 16.2 | 14.1 | - | 5.3 | 14.1 | 24.1 | - | 43.5 | 26090.8 | 1438.8 | - | - | - | 4431.2 | 5059.0 | 1043.1 | 3591.5 | 6394.1 | 59.2 | - | - | 77.9 | 77.9 | - | - | 45.6 | 45.6 | - | - | 182.5 | 1046.9 | 978.8 | 1200.8 | 580.7 | 66.4 | 129.9 | 273.8 | 136.9 | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
64.3 | 46.0 | 50.5 | - | 35.8 | 27.2 | 26.6 | - | 27.2 | 16.2 | 14.1 | - | 5.3 | 14.1 | 24.1 | - | 43.5 | -28906.9 | 1438.8 | - | - | - | 4431.2 | 5059.0 | 1043.1 | 3591.5 | 6394.1 | 59.2 | - | - | 77.9 | 77.9 | - | - | 45.6 | 45.6 | - | - | 182.5 | 1046.9 | 978.8 | 1200.8 | 580.7 | 66.4 | 129.9 | 273.8 | 136.9 | - | - | - | - | - | - | - | - |
All numbers in USD currency